The Weekly Wire
A weekly behavioral-health intelligence briefing: what moved, why it matters, and what to watch next.
Compass Pathways, Helus Pharma, Incannex and Usona rely on outside manufacturers, and Compass, the closest to market, plans to deliver through clinics it does not run. Their disclosures show a prescription market being assembled from clinical-supply contracts, research collaborations and a clinic base that esketamine built, with one software company working with three drug developers.
In a request for information published October 6, FDA described the early-phase ibogaine trial it is considering: single ascending doses up to 10 mg/kg, given one participant at a time in an inpatient unit equipped to treat a life-threatening arrhythmia. The notice sets no requirements. It does show what a sponsor would likely need under that approach, and the first item is a hospital, which neither funding nor drug supply provides on its own.
Starting in 2027, VA plans to require a signed consent form before prescribing an antidepressant to a veteran younger than 30. Ten months earlier it told the Senate a broader signature mandate could delay care. It has not explained the age line, and the FDA's own trial analysis did not find added suicidality risk at ages 25 to 34.
Flow Neuroscience's FL-100 headset is the only tDCS device with a completed FDA premarket approval for depression; its closest rivals are still in investigational trials. The commercial launch adds a prescription and telehealth pathway to that approval. It does not add a price, an insurance answer, or independent data on how the device performs outside a clinical trial.
FDA's September 14 public hearing opened with five minutes on executive orders and priority vouchers, then turned to a two-hour comment block on a narrower question: who has to be in the room when a patient takes the drug. This account covers the opening remarks and twenty of that block's speakers. Not one of them drew a question from FDA's panel.
Cancer pain, chronic pelvic pain, phantom limb pain, fibromyalgia, migraine: psilocybin trials are now running across a genuinely wide swath of chronic pain medicine. Nearly all of them share the same structural weakness, a pain-scale endpoint that cannot tell whether the drug changed the pain itself or changed how much the pain bothers the patient. That distinction is the entire story.
A retrospective study of 19 patients treated under Switzerland's limited medical-use exemption is among the first real-world psilocybin outcome data generated outside a clinical trial. The response and remission rates land close to what ordinary antidepressants achieve in real-world use, not the dramatic figures the field's early trials reported.
A retrospective analysis of 3,041 Mindbloom patients reports high rates of clinical improvement from at-home subcutaneous ketamine, a genuinely under-studied delivery route. The topline numbers are real. So is the conflict of interest, the near-total attrition by the final assessment, and the gap between the headline improvement rate and the much lower remission rate underneath it.
Draulio B. Araújo's research moved from studying consciousness during the acute ayahuasca experience to a randomized trial in treatment-resistant depression, and now to an ongoing Phase 2b DMT study built specifically to find out whether that early signal survives blinding, an active comparator, and outcomes that go beyond a symptom scale.
Read the piece →Track regulation, market movement, pipeline status, and news signals across pharma, psychedelics, cannabis, and digital health.
Plain-language context behind the industry headlines — no jargon, no hype.
What the trials actually show, where the FDA stands, and what "breakthrough" does and doesn't mean.
Read the coverage →New antidepressants, postpartum drugs, and fast-acting options — and why approval doesn't equal access.
Read the coverage →Telehealth, therapy apps, and AI tools — what's regulated, what works, and what to watch for.
Read the coverage →Phases, endpoints, and what "statistically significant" does and doesn't guarantee — a guide to the filings in our tracker.
Read the guide →Free, confidential crisis lines and guidance on finding real care — available 24/7.
Get help →